Cholesterol: The Full Picture Beyond LDL
The relationship between cholesterol and heart disease is real but far more nuanced than the simple “LDL is bad” model taught for decades. LDL cholesterol is better understood as a heterogeneous population of particles varying in size and density: small, dense LDL particles penetrate arterial walls far more readily than large, buoyant ones and are three times more atherogenic per unit mass. Standard LDL cholesterol tests do not distinguish between these phenotypes. LDL particle number (LDL-P) and apolipoprotein B (ApoB) — which counts each individual LDL particle — are more accurate predictors of cardiovascular risk than standard LDL cholesterol, particularly in people who appear to have normal LDL but carry a dense, small-particle phenotype called “Pattern B.”
Triglycerides and HDL cholesterol interact in a risk ratio that often matters more than LDL alone. A triglyceride-to-HDL ratio above 3.0 strongly predicts insulin resistance and small, dense LDL particle prevalence even when standard LDL appears normal. This ratio explains why some people with LDL of 130 mg/dL have minimal arterial disease while others with LDL of 90 mg/dL have extensive plaques — the metabolic context of those LDL particles determines their behavior. Reducing triglycerides through carbohydrate reduction and omega-3 supplementation while raising HDL through exercise simultaneously shifts LDL particles from the dangerous small, dense phenotype toward the benign large, buoyant pattern.
Lipoprotein(a) — Lp(a) — is the most under-discussed major cardiovascular risk factor. Lp(a) is a modified LDL particle that is both atherogenic and thrombotic, and its levels are approximately 90% genetically determined, making lifestyle modification largely ineffective. Elevated Lp(a) (above 50 mg/dL or 125 nmol/L) doubles cardiovascular risk and is present in approximately 20% of the population. Standard lipid panels do not include Lp(a). Every adult should have at least one Lp(a) measurement in their lifetime — if elevated, it mandates aggressive management of all other modifiable risk factors and motivates earlier pharmacological intervention. RNA interference therapies specifically targeting Lp(a) are currently in late-stage clinical trials.
Statins remain the most evidence-based pharmacological tool for cardiovascular prevention, with a meta-analysis of 26 trials encompassing 170,000 participants showing a 22% reduction in major cardiovascular events per 1 mmol/L reduction in LDL cholesterol. However, statins work primarily by reducing LDL particle number, not simply LDL mass — the ApoB reduction from statin therapy is what mechanistically prevents plaques. For statin-intolerant patients, PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL by 50-60% on top of statin therapy and have demonstrated 15% cardiovascular event reductions. Inclisiran, a twice-yearly injection targeting the same pathway, represents a significant advance in medication adherence — one of the greatest challenges in chronic disease management.